Antiplatelet therapy in peripheral artery disease

Area of Science:

• Cardiovascular Medicine
• Vascular Surgery
• Pharmacology

Background:

• Peripheral artery disease (PAD) involves atherosclerosis and lower extremity artery narrowing, affecting 12% of adults.
• PAD patients face a high risk of cardiovascular events (myocardial infarction, stroke, vascular death), despite low peripheral complication rates.
• Symptoms include claudication and critical limb ischemia, but up to 50% of cases are asymptomatic PAD.

Purpose of the Study:

• To evaluate the effectiveness of antiplatelet therapy in reducing cardiovascular risk in PAD patients.
• To investigate the differential efficacy of aspirin versus non-aspirin antiplatelet agents in PAD.
• To identify the need for further research on aspirin and novel antiplatelet drugs in PAD management.

Main Methods:

• Analysis of data from the Antithrombotic Trialists' Collaboration on antiplatelet treatment in PAD.
• Assessment of cardiovascular risk using the ankle-brachial index (ABI) diagnostic test (≤0.90 for PAD).
• Review of existing literature on antiplatelet drug efficacy in PAD, including clopidogrel and dipyridamole.

Main Results:

• Antiplatelet therapy demonstrated a 23% risk reduction in vascular events for the overall PAD population.
• Non-aspirin antiplatelet drugs (e.g., clopidogrel) were largely responsible for the observed benefits in PAD.
• Aspirin's efficacy in reducing atherosclerotic progression in PAD remains questionable compared to its role in coronary heart disease.

Conclusions:

• Further trials are warranted to assess aspirin's efficacy in both symptomatic and asymptomatic PAD patients (ABI ≤0.90).
• The role of newer antiplatelet agents like prasugrel and ticagrelor in PAD management requires investigation.
• Optimizing antiplatelet strategies is crucial for mitigating cardiovascular risk in the PAD population.